Following this, Venus Remedies' scrip tumbled 20 per cent to settle at Rs 302.80 on the BSE.
At the NSE, the stock plunged 19.99 per cent to close at Rs 302.10.
Led by the dip in the stock, the company's market value fell by Rs 86.54 crore to Rs 346.46 crore.
On the volume front, 10.80 lakh shares of the company changed hands at the BSE, while over 31 lakh shares were traded at the NSE during the day.
The rating downgrade reflects delays in repayment of term loan by the company driven by a stretched liquidity, the rating agency said.
VRL's stretched liquidity is on account of the significant increase in total cost of the large debt-funded capital expenditure over the past one year and high working capital requirements, CRISL said in a report issued yesterday.
The company is undertaking capex towards setting up marketing office. The total cost of this capex is estimated to have increased by about Rs 100 to 150 million. In addition to the above company's liquidity has also deteriorated on account of the high working capital requirements reflected by inventory of about 131 days as on March 31, 2014.
The ratings also factor in the company's strong presence in the high-value critical care segment and the healthy growth in its domestic and export sales.
For arriving at the ratings, Crisil has combined the business and financial risk profiles of VRL and its wholly owned subsidiary, Venus Pharma GmbH (VP), based in Germany. VP provides out-licensing services of common technical documents, and warehousing and logistical support to VRL. The two entities have together been referred to as VRL, Crisil added.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
